Clinical Trial Update: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV [Phase 2]

View source ↗

Summary

Phase 2 trial of the oral TLR8 agonist Selgantolimod (GS-9688) on HBsAg in participants with chronic hepatitis B and HIV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis B

Drugs mentioned

• Selgantolimod (Selgantolimod)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hepatitis B, HIV Infections | Phase 2 | Status: COMPLETED